Abbott’s i-STAT, a portable blood clinical analyzer, has been found to improve decision making in healthcare settings. Data presented at the European Society for Emergency Medicine (EuSEM) Congress held in October 2015 in Italy confirmed that the i-STAT handheld analyzer has the capability to provide clinicians with the information needed for quick decision making, thereby promoting effective and efficient care.
This point-of-care device can simplify the testing process even in busy health care environments. More than 50,000 i-STAT analyzers are in use worldwide, helping to process approximately 50 million test cartridges each year. The current version measures 26 different analytes or substances in the body across 19 different testing cartridges.
Highlights of findings presented at the EuSEM Congress:
- i-STAT technology proved useful in helping with diagnosis, decision-making and treatment in ambulances/mobile intensive care environments.
- In the Emergency Department, the average length of stay for patients was reduced by nearly an hour when i-STAT was used.
- With this technology, the availability of troponin testing improved to 15 minutes, compared to an average of 72 minutes for traditional lab testing.
- The wireless device can automatically transfer a patient’s results to the electronic medical record (EMR), thereby replacing manual entry and reducing the risk of human error.
Along with built-in quality check systems by design, this FDA-cleared point of care analyzer features single-use disposable test cartridges for a broad menu of diagnostic tests, including cardiac markers, blood gases, chemistries/electrolytes, coagulation, lactate and hematology.
The easy testing process with this lightweight device involves the physician entering patient information into the handheld device, placing two or three blood drops on the testing cartridge, inserting the cartridge into the device, and viewing the test results at a patient’s bedside in as little as 2 minutes for most cartridges. Appropriate training is necessary to ensure that the platform is used properly and maintains local regulatory requirements.
Abbott is continuing its good work on assays/product developments.
SelectScience reports that Katie Mims, Director of Clinical Affairs, Point-of-Care, Abbott said, “Abbott is currently working to develop an expanded testing menu focused on cardiac, thyroid, neuroscience and blood conditions as well as a next-generation i-STAT System to improve efficiencies, drive down costs and improve patient care”.